TRPM2 and metabolic dysfunction-associated steatotic liver disease: The activation of the TRPM2/Ca2+/CaMKII signaling pathway promotes lipid accumulation, mitochondrial damage, and ERS, which aggravates the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH), then to cirrhosis and ultimately, to liver cancer [109].